FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002204518> ?p ?o ?g. }

• W2002204518 endingPage "859" @default.
• W2002204518 startingPage "853" @default.
• W2002204518 abstract "Concomitant treatment with radiation therapy and cisplatin (CDDP) remains the gold standard for bladder preservation in the treatment of muscle-invasive bladder cancer (MIBC). We present the long-term results of a phase 1 clinical trial to assess the association of twice-weekly gemcitabine with CDDP and radiation therapy in this setting.Patients with pT2-pT4N0M0 MIBC without hydronephrosis or diffuse carcinoma in situ were enrolled in this study. After maximal transurethral resection of the bladder tumor, patients received concomitant radiation therapy (63 Gy in 1.8 fractions) and chemotherapy (CDDP 20 mg/m²/day over 4 days every 21 days and gemcitabine twice a week). The starting dose of gemcitabine was 15 mg/m² with dose escalation to 20, 25, and 30 mg/m². The primary endpoint was the maximum tolerated dose (MTD). Secondary endpoints included toxicity and tumor control.Fourteen patients were enrolled. Dose-limiting toxicity occurred in 2 patients treated with 30 mg/m² gemcitabine (grade 4 thrombocytopenia and severe impairment of World Health Organization performance status, respectively). Nine patients received the complete chemoradiation therapy protocol. The recommended dose of gemcitabine was 25 mg/m². The median follow-up time was 53 months, and the overall and disease-specific 5-year survival rates were 62% and 77%, respectively. Among the patients who received the complete treatment, bladder-intact survival was 76% at 5 years, and the median overall survival was 69.6 months.This regimen was well tolerated. The gemcitabine MTD was 25 mg/m². Bladder preservation and disease control were promising. A multicenter phase 2 randomized trial is ongoing." @default.
• W2002204518 created "2016-06-24" @default.
• W2002204518 creator A5010459987 @default.
• W2002204518 creator A5020273248 @default.
• W2002204518 creator A5031202796 @default.
• W2002204518 creator A5042877629 @default.
• W2002204518 creator A5046071506 @default.
• W2002204518 creator A5064546314 @default.
• W2002204518 creator A5077576453 @default.
• W2002204518 creator A5090993023 @default.
• W2002204518 date "2014-03-01" @default.
• W2002204518 modified "2023-10-17" @default.
• W2002204518 title "Combined Chemoradiation Therapy With Twice-Weekly Gemcitabine and Cisplatin for Organ Preservation in Muscle-Invasive Bladder Cancer: Long-Term Results of a Phase 1 Trial" @default.
• W2002204518 cites W1504077841 @default.
• W2002204518 cites W1774531900 @default.
• W2002204518 cites W1975246874 @default.
• W2002204518 cites W1985950314 @default.
• W2002204518 cites W1992548667 @default.
• W2002204518 cites W2008698822 @default.
• W2002204518 cites W2028522982 @default.
• W2002204518 cites W2031079883 @default.
• W2002204518 cites W2032140001 @default.
• W2002204518 cites W2037359875 @default.
• W2002204518 cites W2072167013 @default.
• W2002204518 cites W2083513265 @default.
• W2002204518 cites W2103257412 @default.
• W2002204518 cites W2103492268 @default.
• W2002204518 cites W2130834017 @default.
• W2002204518 cites W2135108459 @default.
• W2002204518 cites W2139817908 @default.
• W2002204518 cites W2140970165 @default.
• W2002204518 cites W2147990977 @default.
• W2002204518 cites W2160797158 @default.
• W2002204518 cites W4211118805 @default.
• W2002204518 doi "https://doi.org/10.1016/j.ijrobp.2013.11.016" @default.
• W2002204518 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24368064" @default.
• W2002204518 hasPublicationYear "2014" @default.
• W2002204518 type Work @default.
• W2002204518 sameAs 2002204518 @default.
• W2002204518 citedByCount "21" @default.
• W2002204518 countsByYear W20022045182014 @default.
• W2002204518 countsByYear W20022045182015 @default.
• W2002204518 countsByYear W20022045182016 @default.
• W2002204518 countsByYear W20022045182017 @default.
• W2002204518 countsByYear W20022045182018 @default.
• W2002204518 countsByYear W20022045182019 @default.
• W2002204518 countsByYear W20022045182020 @default.
• W2002204518 countsByYear W20022045182021 @default.
• W2002204518 countsByYear W20022045182023 @default.
• W2002204518 crossrefType "journal-article" @default.
• W2002204518 hasAuthorship W2002204518A5010459987 @default.
• W2002204518 hasAuthorship W2002204518A5020273248 @default.
• W2002204518 hasAuthorship W2002204518A5031202796 @default.
• W2002204518 hasAuthorship W2002204518A5042877629 @default.
• W2002204518 hasAuthorship W2002204518A5046071506 @default.
• W2002204518 hasAuthorship W2002204518A5064546314 @default.
• W2002204518 hasAuthorship W2002204518A5077576453 @default.
• W2002204518 hasAuthorship W2002204518A5090993023 @default.
• W2002204518 hasBestOaLocation W20022045182 @default.
• W2002204518 hasConcept C121608353 @default.
• W2002204518 hasConcept C126322002 @default.
• W2002204518 hasConcept C126894567 @default.
• W2002204518 hasConcept C141071460 @default.
• W2002204518 hasConcept C143998085 @default.
• W2002204518 hasConcept C203092338 @default.
• W2002204518 hasConcept C2776694085 @default.
• W2002204518 hasConcept C2779384505 @default.
• W2002204518 hasConcept C2780258809 @default.
• W2002204518 hasConcept C2780352672 @default.
• W2002204518 hasConcept C2781413609 @default.
• W2002204518 hasConcept C29730261 @default.
• W2002204518 hasConcept C509974204 @default.
• W2002204518 hasConcept C535046627 @default.
• W2002204518 hasConcept C71924100 @default.
• W2002204518 hasConcept C90924648 @default.
• W2002204518 hasConceptScore W2002204518C121608353 @default.
• W2002204518 hasConceptScore W2002204518C126322002 @default.
• W2002204518 hasConceptScore W2002204518C126894567 @default.
• W2002204518 hasConceptScore W2002204518C141071460 @default.
• W2002204518 hasConceptScore W2002204518C143998085 @default.
• W2002204518 hasConceptScore W2002204518C203092338 @default.
• W2002204518 hasConceptScore W2002204518C2776694085 @default.
• W2002204518 hasConceptScore W2002204518C2779384505 @default.
• W2002204518 hasConceptScore W2002204518C2780258809 @default.
• W2002204518 hasConceptScore W2002204518C2780352672 @default.
• W2002204518 hasConceptScore W2002204518C2781413609 @default.
• W2002204518 hasConceptScore W2002204518C29730261 @default.
• W2002204518 hasConceptScore W2002204518C509974204 @default.
• W2002204518 hasConceptScore W2002204518C535046627 @default.
• W2002204518 hasConceptScore W2002204518C71924100 @default.
• W2002204518 hasConceptScore W2002204518C90924648 @default.
• W2002204518 hasIssue "4" @default.
• W2002204518 hasLocation W20022045181 @default.
• W2002204518 hasLocation W20022045182 @default.
• W2002204518 hasLocation W20022045183 @default.
• W2002204518 hasLocation W20022045184 @default.
• W2002204518 hasOpenAccess W2002204518 @default.
• W2002204518 hasPrimaryLocation W20022045181 @default.

• next